Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Zanubrutinib plus R-CHOP versus R-CHOP as first-line therapy in double-expressor DLBCL: A multicenter, propensity score matched retrospective study

View Full Paper
Ask AI
Bookmark
Share

Authors

QCQingqing CaiHYHang YangYJYirong Jiang

Discussion

Loading...

Member takes

Overview

Retrospective study shows improved progression-free survival in double-expressor DLBCL with ZR-CHOP, indicating enhanced treatment efficacy.

Key Points

  • Overall survival improves significantly with zanubrutinib plus R-CHOP compared to R-CHOP alone.
  • Retrospective analysis demonstrated a 1-year progression-free survival of 90.4% in ZR-CHOP versus 66.3% in R-CHOP.
  • Patient groups were matched using propensity score matching to reduce bias, ensuring comparability of outcomes.
  • Study highlights potential benefits of combining BTKis like zanubrutinib with conventional therapies for DLBCL.

Cite This Study

Cai et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e290https://doi.org/10.1182/blood-2025-7202
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Zanubrutinib in combination with R-CHOP for previously untreated mcd type of Diffuse large b-cell lymphoma (DLBCL).2025
  2. 2Efficacy and safety of zanubrutinib combined with chemotherapy in the treatment of relapsed/refractory diffuse large B-cell lymphoma2025
  3. 3ZAP trial: MRD-guided chemotherapy and maintenance de-escalation with zanubrutinib-g-CHOP in high-risk FL (Phase II)2025
  4. 4A phase 2 study of zanubrutinib in combination with rituximab and lenalidomide in de novo diffuse large B-cell lymphoma2025 · 5 citations
  5. 5Ibrutinib plus R-CHOP followed by maintenance in untreated ABC-DLBCL patients with IPI ≥2: A first analysis of phase II Study  FIL_RI-CHOP2025